Another patient in our cohort with an FAB M2 phenotype, classified as high risk according to the AML-BFM 2020 study protocol due to trisomy of chromosome 8 and mutations in NRAS, WT1, and FLT3, showed resistance in our ex vivo profiling and did not respond to induction chemotherapy but could eventually undergo successful allogenic hematopoietic stem cell transplantation after late response and has remained in remission since (Figures S3E–S3H). The gene discussed is FLT3; the disease is acute myeloid leukemia.